GlassScriptPhysician profile
Alison Alderin
NPI 1992170476
$2,543.45
in general payments reported to CMS, 2019-2025
32 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,040 · 2022: $561 · 2023: $448 · 2024: $227 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $603.47 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $239.78 | 2021-2025 | Breztri, Airsupra, Lokelma |
| Abbvie INC. | $225.21 | 2021-2023 | |
| Amgen INC. | $151.23 | 2021-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.26 | 2021-2023 | Jardiance, Tradjenta, Synjardy |
| Boston Scientific Corporation | $130.36 | 2021-2025 | General - Pain Management |
| Merck Sharp & Dohme LLC | $117.87 | 2021-2025 | Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.33 | 2021-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $74.91 | 2021-2024 | Veozah |
| Glaxosmithkline, LLC. | $70.26 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $65.73 | 2021 | |
| Pfizer INC. | $47.85 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.15 | 2021-2022 | |
| Antares Pharma, INC. | $45.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.53 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $44.00 | 2021-2022 | |
| Exact Sciences Corporation | $42.76 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $42.49 | 2021 | |
| Corcept Therapeutics | $38.00 | 2024 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $37.23 | 2023 | Eliquis |
| Daiichi Sankyo INC. | $35.02 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.87 | 2023 | Quviviq |
| Ultragenyx Pharmaceutical INC. | $22.36 | 2023 | |
| Sanofi Pasteur INC. | $19.51 | 2023 | |
| Sumitomo Pharma America, INC. | $18.90 | 2023 | Aptiom |
| Scilex Pharmaceuticals INC. | $18.84 | 2023 | Ztlido |
| Organogenesis INC. | $17.27 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.24 | 2025 | Caplyta |
| Dexcom, INC. | $14.95 | 2023 | Dexcom G6 Transmitter |
| Eisai INC. | $14.11 | 2021 | |
| Genentech USA, INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Alderin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.